Drugs / MVA Pfs25-IMX313
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02532049 Comparator | Oct 2015 → May 2017 | malaria | University of Oxford | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVA Pfs25-IMX313 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02532049 ↗ |
| Modality | Vaccine | “two recombinant viral vectored vaccines encoding Pfs25-IMX313” PMID 34335606 ↗ Jul 2021 |
| Route | Intramuscular | “All vaccines will be administered intramuscularly.” NCT02532049 ↗ |